Recent studies suggest that the concentration and genotype of Vitamin D binding protein (DBP) are important factors that determine the bioavailability of 25OH Vit D in blood. It has been suggested that measurement of free, non-protein bound 25OH Vit D in serum, may provide more relevant diagnostic information than total 25OH Vit D, for instance in chronic kidney disease, bladder cancer and pancreatic cancer, or in hemodialysis patients [1][2][3][4][5][6][7][8][9] . To measure Free 25OH Vit D in blood Future Diagnostics developed a direct ELISA method. Following the first laboratory evaluation phase, a two-step enzyme-linked immunosorbent assay (ELISA) was optimized for the quantification of free 25OH Vit-D assay 10,11 . Modifications were made in the protocol for the coating of the monoclonal anti-25OH Vit-D in the microtiter plates as well as in the formulation of the sample diluent and of the biotinylated Vitamin D conjugate. The optimized assay was validated and showed the following performances: the calibrator range is 0.2-35 pg/ml. Total assay precision is 10.2% at 6.0 pg/ml, 7.6% at 10.9 pg/ml and 5.5% at 24.9 pg/ml. The crossreactivity of the antibody towards 25OH Vitamin D2 is 77% and the influence of interfering hemoglobin, bilirubin and triglycerides was also verified being lower than 10%. Additional experiments have shown that the addition of albumin or Vitamin D Binding Protein to serum leads to a decrease in the observed level of free 25OH Vit-D.
Introduction
The principle of the assay. During the first incubation step free 25OH Vitamin D binds to the monoclonal anti-Vitamin D in the microtiter plate. The in vivo equilibrium between free and bound 25OH Vitamin D is minimally disturbed by the use of a specific displacement reagent. After washing, a fixed amount of biotinylated 25OH Vitamin D is added to each well. The non-bound biotinylated 25OH Vitamin D is removed by washing and a streptavidin peroxidase conjugate is added. In the next step TMB substrate is added. Next the reaction is stopped and the absorbance is measured using a plate reader.
Results

Protocol Manual
• Add 90 µL of sample diluent into the wells.
• Add 10 µl samples into the well.
• Incubate shaking (orbital) 90 min at 37 °C • Wash • Add 100 µL biotin-25(OH) VitD into each well.
• Incubate shaking (orbital) 30 min at 37°C.
• Wash • Add 100 µL of strep-HRP into each well • Incubate shaking (orbital) for 20 min at 37 °C.
• Wash • Add 100 µL of TMB substrate into each well.
• Incubate 15 minutes at RT in the dark.
• Add 100 µL Stop Solution into each well.
• Read the absorbance at 450 nm.
Protocol Dynex DS2
• Add 90 µl of sample diluent into the wells.
• Add 10 µl sample in to the well.
• Incubate shaking(linear) 90 min at 37°C • Wash • Add 100µl biotin-25(OH) VitD into each well • Incubate shaking (linear) 30 min at 37°C.
• Wash • Add 100 µL of strep-HRP into each well.
• Incubate shaking (linear) for 20 min at 37 °C.
• Shake 5 seconds.
• Read the absorbance at 450 nm 
Limit of Blank & Limit of Detection
The LoB and LoD in pg/mL were determined according to CLSI EP17-A2. For LoB 38 reps were measured. For LoD 4*38 reps were measured.
